PRT-811
Prelude Therapeutics
['melanoma']
prt811 demonstrated clinical activity and an acceptable safety profile in patients with idh+ recurrent, high-grade glioma and splicing mutation-positive uveal melanoma treated in the dose-expansion stage of a phase 1 study. #asco2023 | 
Oncology news and insights from leading researchers and cancer centers.